XML 81 R50.htm IDEA: XBRL DOCUMENT v3.22.1
Note 4 - Collaboration Revenue - Schedule of Collaboration Revenue (Details) - USD ($)
$ in Thousands
1 Months Ended 12 Months Ended
Nov. 30, 2020
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Proceeds from issuance of contingently redeemable noncontrolling interests, net of issuance cost   $ 0 $ 5,233 $ 0
SEED Therapeutics Inc. [Member] | Research Collaboration and License Agreement with Eli Lilly [Member]        
Collaboration arrangement $ 10,000   9,455  
Proceeds from issuance of contingently redeemable noncontrolling interests, net of issuance cost     5,267  
Fair value of the Forward (Note 16)     278  
Total cash proceeds     $ 15,000